ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025
Investigation of a measles outbreak in a highly vaccinated middle school, France, 2023.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In September 2023, a measles outbreak occurred in a middle school (Rhône valley, France), with the index case returning from Asia. Investigations involved case validation, virological analyses, contact tracing and checking vaccination records to determine measles vaccination coverage (VC) and attack rates (AR). Among 643 students, 49 measles cases occurred between 6 September and 18 October 2023 (AR = 7.6%). Two-dose vaccination coverage was 93.5% (601/643). Virological analyses confirmed the measles strains' clonality (genotype D8) and the imported origin. Concordance between health record vaccination status and immunological profile was established for 27 cases. In a sub-cohort of children (all cases and 309 non-cases), AR was 100% in unvaccinated children, and 43.7%, 16.5% and 3.2% among two-dose vaccinated children with the first dose administered at 6-8, 9-11 and ≥ 12 months, respectively. After multivariate binomial regression, vaccine effectiveness (VE) was 96.4% (95% confidence interval (CI): 91.4-98.5) after two-dose vaccination with the first dose at ≥ 12 months, confirming long-term effectiveness of measles-mumps-rubella vaccines. When the first dose was given at 9-11 and 6-8 months, respectively, VE was 83.3% (95% CI: 74.3-89.2) and 60.7% (95% CI: 10.6-82.7). This measles epidemic mainly affected unvaccinated or two-dose vaccinated children with first dose administered before age 12 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.